DRDR:LSE:LSE-iShares Healthcare Innovation UCITS ETF USD (Acc) (GBX)

ETF | Others |

Last Closing

USD 601

Change

+1.13 (+0.19)%

Market Cap

USD 1.08B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-20 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

N/A

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

N/A

USD 292,109.19B
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 652.47B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 650.46B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 330.91B

ETFs Containing DRDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.56% 34% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.56% 33% F 39% F
Trailing 12 Months  
Capital Gain -3.61% 12% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.61% 12% F 28% F
Trailing 5 Years  
Capital Gain 23.71% 43% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.71% 41% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 6.10% 58% F 63% D
Dividend Return 6.10% 57% F 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 22.96% 28% F 42% F
Risk Adjusted Return 26.58% 50% F 62% D
Market Capitalization 1.08B 81% B- 69% C-

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.